Laman UtamaTWST • NASDAQ
add
Twist Bioscience Corp
$39.24
Selepas Waktu Dagangan:(0.00%)0.00
$39.24
Tutup: 2 Mei, 4:01:57 PTG GMT-4 · USD · NASDAQ · Penafian
Tutup sebelumnya
$37.71
Julat hari
$38.45 - $40.45
Julat tahun
$33.16 - $60.90
Permodalan pasaran
2.34B USD
Bilangan Purata
1.19J
Nisbah P/E
-
Hasil dividen
-
Pertukaran utama
NASDAQ
Dalam berita
Kewangan
Penyata Pendapatan
Hasil
Pendapatan bersih
| (USD) | Dis 2024info | Perubahan T/T |
|---|---|---|
Hasil | 88.71J | 24.08% |
Perbelanjaan pengendalian | 77.48J | 2.03% |
Pendapatan bersih | -31.59J | 26.54% |
Margin untung bersih | -35.61 | 40.80% |
Pendapatan bagi setiap syer | -0.53 | 29.33% |
EBITDA | -28.26J | 27.17% |
Kadar cukai berkesan | -0.31% | — |
Kunci Kira-kira
Jumlah aset
Jumlah liabiliti
| (USD) | Dis 2024info | Perubahan T/T |
|---|---|---|
Pelaburan tunai dan jangka pendek | 270.83J | -12.96% |
Jumlah aset | 608.58J | -16.95% |
Jumlah liabiliti | 152.64J | 6.91% |
Jumlah ekuiti | 455.94J | — |
Syer tertunggak | 59.65J | — |
Harga kepada buku | 4.93 | — |
Pulangan pada aset | -14.16% | — |
Pulangan pada modal | -15.80% | — |
Aliran Tunai
Perubahan bersih dalam tunai
| (USD) | Dis 2024info | Perubahan T/T |
|---|---|---|
Pendapatan bersih | -31.59J | 26.54% |
Tunai daripada operasi | -21.43J | 6.73% |
Tunai daripada pelaburan | -1.54J | -136.88% |
Tunai daripada pembiayaan | 17.94J | 1,318.19% |
Perubahan bersih dalam tunai | -5.07J | 74.84% |
Aliran tunai bebas | -11.25J | -3.00% |
Perihal
Twist Bioscience is a public biotechnology company based in South San Francisco that manufactures synthetic DNA and DNA products for customers in a wide range of industries. Twist was founded in 2013 by Emily Leproust, Bill Banyai, and Bill Peck.
The company was represented by Leproust at a March 2021 tabletop exercise at the Munich Security Conference simulating an outbreak of weaponized monkeypox.
In May 2021, Twist Bioscience and Genome Project-Write launched a new CAD platform for whole genome design. The CAD will automate workflows to enable collaborative efforts critical for scale-up from designing plasmids to megabases across entire genomes. Wikipedia
Diasaskan
2013
Tapak web
Pekerja
923
